Eli Lilly to acquire AtaiBeckley for $2.8 billion

Lobe Sciences Ltd. announced that Chairman and Chief Executive Officer Dr. Frederick D. Sancilio will present clinical and preclinical data for Conjugated Psilocin, or L-130, at the 9th Neuropsychiatric Drug Development Summit, held September 15-17, 2026 in Boston, Massachusetts. Dr. Sancilio's presentation, titled "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm," is scheduled for 11:00 a.m. ET on Wednesday, September 16 in the summit's preclinical and translational track. The presentation sets out the case for patented L-130 as a candidate suited to daily outpatient dosing rather than the supervised in-clinic administration that psychedelic-class candidates typically require, covering the compound's formulation characteristics as a patented salt of psilocin, the active moiety itself rather than a prodrug, together with first-in-human results in ten subjects showing consistent oral pharmacokinetics and preclinical findings on daily low-dose administration. Lobe will also exhibit throughout the three-day summit, which brings together senior discovery, translational, clinical, regulatory and business development leaders from large pharmaceutical companies, biotechnology companies and investors active in neuropsychiatric drug development. L-130 is initially being developed for cluster headache, with co-development programs underway for PTSD, substance use disorder, generalized anxiety disorder and other neuropsychiatric disorders, while the company is also advancing S-100 for sickle cell disease, with Phase 3 clinical development anticipated to commence in mid-2027.